Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiologyheart failure, electrophysiologyhypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

Abbott's Espirit BTK Everolimus Eluting Resorbable Scaffold gained U.S. FDA approval in April 2024. It is based on the former Abbott Absorb coronary stent, but indicated for use in peripheral artery lesions below the knee (BTK).

FDA approves Abbott’s resorbable stent for BTK arteries

The bioresorbable stent, examined at length for the LIFE-BTK clinical trial, stays in place for up to three years before completely dissolving. 

H5N1 bird flu in cows

Worries rise over bird flu in cows

Infectious disease experts are ratcheting up their watchfulness of the H5N1 influenza virus. That’s because the strain of “bird flu” has continued turning up in domestic livestock.

Thumbnail

Society of Thoracic Surgeons launches new risk calculators for SAVR after TAVR, other key heart surgeries

STS risk calculators are known as a go-to resource for cardiologists, surgeons and any other healthcare providers who manage the care of heart patients. 

Confirmed: AFib ablation more beneficial for patients with HFrEF than those with HFpEF

Researchers explored data from nearly 2,500 AFib ablation patients, sharing their findings in JAMA Cardiology.

An 86-year-old patient is showing signs of improvement six months after receiving the world’s first implant of a new-look medical device for treating tricuspid regurgitation (TR), according to new data published in JACC: Cardiovascular Interventions.[1] The device in question, the Tricuspid Flow Optimizer, was developed by Triflo Cardiovascular, a U.S.-based biomedical company founded in 2017 by a team of structural heart specialists.

Cardiologists share update after world’s first implant of new optimizer device for tricuspid regurgitation

The Tricuspid Flow Optimizer was developed by Triflo Cardiovascular, a U.S.-based healthcare technology company founded by structural heart specialists.

Thumbnail

Could diamond dust replace gadolinium in MRI contrast agents?

An accidental discovery could have future implications for the material makeup for MRI contrast media.

Thumbnail

Cardiology groups share key update: ABMS seeking feedback on proposed Board of Cardiovascular Medicine

Five of the largest U.S. medical societies focused on cardiovascular health are one step closer to seeing their paradigm-shifting proposal become a reality.

FDA clears ICE Aspiration System

FDA clears new catheter for peripheral blood clots

The new-look catheter came out of a medical device incubator started by entrepreneur Eitan Konstantino, PhD, who has years of experience in the vascular space.